

Journal of Medical Genetics Special Issue Call for Papers:
Genomic aspects of cancer immunotherapy: challenges and clinical implications

Guest Editors: Professor Xiao-Jie Lu and Professor Beicheng Sun

Submission start: December 2017

Submission deadline: April 2018

Aim and Scope:

This special issue in *Journal of Medical Genetics (JMG)* aims at publishing high-quality original research as well as reviews on genomic aspects of cancer immunotherapy. Authors should bear in mind when preparing their papers that *JMG* is a genetics journal and thus papers must have genetic relevance.

Potential topics of interest include but are not limited to:

1. Epigenetic/genetic modifications of T and B lymphocytes for therapeutic purposes (clinical or pre-clinical)
2. Targeting the genomics/epigenomics of tumor stromal cells for cancer immunotherapy;
3. Genetic variants (such as HLA) that might impact the efficacy and/or side-effects of cancer immunotherapy
4. Functional genomics in T cell exhaustion
5. Genomic aspects of checkpoint blockage therapy
6. TCR sequencing by next generation sequencing (NGS)
7. The applications of CRISPR-Cas9 in cancer immunotherapy, such as TCR and/or CAR modifications

Article types:

- **Original research:** 6-7 full length articles
- **Brief report:** 2-3 brief reports
- **Reviews:** 1-2 review articles

Please follow the [JMG guidelines for preparation of manuscripts](#). When submitting your manuscript on ScholarOne ensure you select the Special Issue Name under step 1:

Special Issue Name
If this is for a special issue or supplement, please select the issue or supplement title below:
Genomic aspects of cancer immunotherapy ▾

Guest Editor Profiles:



Name: Professor Xiao-Jie Lu

Position: Physician-scientist

Affiliation: Nanjing Medical University, Shanghai Jiaotong University

Email Address: 189@whu.edu.cn

Dr. Xiao-Jie Lu got his master's degree in Wuhan University and doctoral degree in Tongji University (Shanghai, China) majoring in internal medicine. The immunotherapies of hepatocellular carcinoma (HCC) is one of his main interests. His publication list includes many papers in top scientific journals such as *Nature Reviews Immunology*, *Gut*, *Journal of Hepatology*, *Trends in Technology*, and *Trends in Pharmaceutical Sciences*. He is also an editor and/or reviewer for several SCI journals.



Name: Professor Beicheng Sun

Position: Senior Surgeon, Vice Dean

Affiliation: The First Clinical Medical School of Nanjing Medical University

Email Address: sunbc@njmu.edu.cn

Professor Sun got his doctoral degree in Nanjing Medical University (Nanjing, China) majoring in general surgery and had post-doctoral training at U Texas Health Science Center at San Antonio (2001-2004). He is a Yangtze River Scholar distinguished professor in China and also a senior surgeon in liver transplantation. He is interested in basic and clinical studies of hepatocellular carcinoma (HCC) especially in immunotherapy. He has received multiple grants and awards in HCC research and has published a number of research papers in top journals such as *Nature Reviews Immunology*, *Cell Metabolism*, *Nature Communications*, *Hepatology*, *Journal of Hepatology*, *Trends in Pharmaceutical Sciences*, *Oncogene*, *Cancer Research*, and *Clinical Cancer Research*.